This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cambridge Major Laboratories Europe, B.V. Announces Successful FDA Inspection At Weert Facility

Stocks in this article: ACAS

WEERT, The Netherlands, October 22, 2013 /PRNewswire/ --

Global pharmaceutical chemistry leader Cambridge Major Laboratories Europe, B.V. (CML-Europe) is pleased to announce the successful completion of its first Food and Drug Administration inspection. The inspection included a pre-approval inspection and general quality systems audit and concluded with no Form 483 being issued.

     (Logo: )

"This successful FDA inspection represents a major milestone for the CML-Europe facility," said Peter van Tilburg, President of CML-Europe. "We place Quality above all else, and I am so proud that the dedication and performance of the CML-Europe team resulted in this successful outcome."

The successful inspection is the culmination of efforts to demonstrate CML-Europe's ability to supply world-class development services and niche commercial APIs to its growing customer base.

"CML-Europe will always be committed to quality and strong leadership, and this commitment is evidenced by two significant recent hires," said Peter van Tilburg. In September 2013, CML-Europe hired Dr. Marcel Schreuder Goedheijt as Director Operations, and Mr. Jan Douwstra as Head of Production. Dr. Schreuder Goedheijt brings a wealth of chemical pharmaceutical and business experience from his previous positions at DSM, DSM Pharma Chemicals, MSD and Diosynth BV. Mr. Douwstra held previous positions at the Academic Medical Centre, Amsterdam and St. Radboud University Medical Centre, Nijmegen, as well as Abbott Healthcare B.V., Solvay Pharmaceuticals B.V. Weesp, and Smit & Zoon B.V. Amersfoort.

Cambridge Major Laboratories, Inc. announced its intent to merge with AAIPharma Services, Corp. on October 2, 2013.

About Cambridge Major Laboratories, Inc.

Cambridge Major Laboratories, Inc. (CML) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The Company produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API), from early preclinical development to commercial manufacturing. Operating from FDA-inspected facilities in the US and Europe, CML is organized along five key Centers of Excellence, including: Process Chemistry, GMP Manufacturing, Solid State Chemistry, Analytical Services, and Quality/Regulatory Compliance. CML is a portfolio company of American Capital, Ltd. (NASDAQ: ACAS).

For more information on the company, visit  

About AAIPharma Services Corp.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs